Questions over covid
Athina Andonatou made this Official Information request to Ministry of Health
The request was partially successful.
From: Athina Andonatou
Dear Ministry of Health,
As an educated citizen of New Zealand who values their freedom and their ability to make their own choices on how best to take care of their health, which I've done for the last 50 years, I have questions about the covid situation.
1) What evidence has our government used to support the validity of the Pcr test?
2) The vaccine by Pfizer has been granted provisional consent so that it can be used in emergency situations, what evidence is used to support that we're in an emergency situation?
3) What if any of the 58 conditions, which Pfizer is expected to address have been addressed?
4) What other vaccinations in New Zealand have been granted indemnity?
5) Pfizer has a track record of unethical and immoral actions, was this a consideration when deciding to purchase the vaccine from them. If not, why not? And why have they been granted indemnity?
I look forward to your response
Yours faithfully,
Athina
From: OIA Requests
Kia ora
Thank you for your requests for official information received 23 March
2021 for:
“1) What evidence has our government used to support the validity of the
Pcr test?
2) The vaccine by Pfizer has been granted provisional consent so that it
can be used in emergency situations, what evidence is used to support that
we're in an emergency situation?
3) What if any of the 58 conditions, which Pfizer is expected to address
have been addressed?
4) What other vaccinations in New Zealand have been granted indemnity?
5) Pfizer has a track record of unethical and immoral actions, was this a
consideration when deciding to purchase the vaccine from them. If not, why
not? And why have they been granted indemnity?”
We have decided to combine your requests into one request. The Ministry's
reference number for your request is: H202103354.
As required under the Official Information Act 1982 we will endeavour to
respond to your request no later than 22 April 2021, being 20 working days
after the day your request was received.
If we are unable to respond to your request within this time frame, we
will notify you of an extension of that time frame.
If you have any queries related to this request, please do not hesitate to
get in touch.
Ngâ mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
From: OIA Requests
Kia ora Athina
Please find attached a partial transfer letter of your request
Ngā mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
From: Ministerial Services
Ref: 2021-1932
Dear Athina,
On behalf of the Ministry of Business, Innovation and Employment I
acknowledge your email of 23^rd March 2021, partially transferred from the
Ministry of Health on 30^th March 2021 requesting under the Official
Information Act 1982 (the Act), the following:
“4) What other vaccinations in New Zealand have been granted indemnity?
5) Pfizer has a track record of unethical and immoral actions, was this a
consideration when deciding to purchase the vaccine from them. If not, why
not? And why have they been granted indemnity?”
Your request is being processed in accordance with the Act and a response
will be sent to you in due course.
If you have any enquiries regarding your request, or its urgency, feel
free to contact us via email at [1][email address].
Nâku noa, nâ
MINISTERIAL SERVICES
Corporate, Governance and Information
Ministry of Business, Innovation and Employment
Level 4, 15 Stout Street, PO Box 1473, Wellington 6140
NZBN 9429000106078
[2]www.govt.nz - your guide to finding and using New Zealand government
services
show quoted sections
References
Visible links
1. mailto:[email address]
2. http://www.govt.nz/
From: RSI-thehive
Good evening Athina,
Please see attached, MBIE’s response to your Official Information Act
request.
Kind regards,
Lisa
Lisa Seng (she/her)
Ministerial Project Co-ordinator
[1]Description: Description: Description: Description: Description:
Description: Description: cid:image001.jpg@01CD1D45.D6A244C0
MINISTRY OF BUSINESS INNOVATION & EMPLOYMENT / HIKINA WHAKATUTUKI
[2]www.govt.nz - your guide to finding and using New Zealand government
services
show quoted sections
References
Visible links
2. http://www.govt.nz/
From: OIA Requests
Kia ora
Please find attached a response to your official information act request
Ngā mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
From: Athina Andonatou
Dear OIA Requests,
This request for further information is in relation to the reply I received from MBIE as it needs further clarification and information
The link you provided me only covered Sittings of 7 November 2017 to 2 September 2020, so I was not able to see the Statements of Indemnity informing the public of those decisions that were provided to the
House of Representatives on 11 February 2021. Please send me the correct link.
Also, please provide me with:
1) The due diligence process used to assess the performance and delivery of
Pfizer’s vaccine
2) What information you used to inform your decision that Pfizer has not been reckless in the development
of its vaccine?
3) You quote that "This assessment has been reinforced through Medsafe’s extensive review of the safety
and effectiveness of the vaccine, with Medsafe granting provisional approval for its use
on 3 February 2021". However, not all of the conditions of Medsafe's provisional approval have been addressed so how can you truly say their has been an extensive review of the safety and effectiveness of the vaccine?
4) You quote that " It is not unexpected for pharmaceutical companies to seek indemnities from governments in circumstances where clinical trials are restricted, or where a purchase agreement is concluded before full trials are completed". Which of these categories does the indemnity granted for the Pfizer vaccination fall under?
5) Please provide the criteria ACC uses to diagnose a "treatment injury" and what evidence one would have to supply to be provided treatment and support for injuries caused by a vaccination.
6) Finally, please provide me with details of how many people have successfully been awarded treatment and support for any vaccine related injury.
Yours sincerely,
Athina Andonatou
From: OIA Requests
Kia ora Athina,
Thank you for your request for official information received on 18 July
2021 for:
"The link you provided me only covered Sittings of 7 November 2017 to 2
September 2020, so I was not able to see the Statements of Indemnity
informing the public of those decisions that were provided to the House of
Representatives on 11 February 2021. Please send me the correct link.
Also, please provide me with:
1) The due diligence process used to assess the performance and delivery
of Pfizer’s vaccine
2) What information you used to inform your decision that Pfizer has not
been reckless in the development of its vaccine?
3) You quote that "This assessment has been reinforced through Medsafe’s
extensive review of the safety and effectiveness of the vaccine, with
Medsafe granting provisional approval for its use on 3 February 2021".
However, not all of the conditions of Medsafe's provisional approval have
been addressed so how can you truly say their has been an extensive review
of the safety and effectiveness of the vaccine?
4) You quote that " It is not unexpected for pharmaceutical companies to
seek indemnities from governments in circumstances where clinical trials
are restricted, or where a purchase agreement is concluded before full
trials are completed". Which of these categories does the indemnity
granted for the Pfizer vaccination fall under?
5) Please provide the criteria ACC uses to diagnose a "treatment injury"
and what evidence one would have to supply to be provided treatment and
support for injuries caused by a vaccination.
6) Finally, please provide me with details of how many people have
successfully been awarded treatment and support for any vaccine related
injury."
The Ministry's reference number for your request is: H202108633.
As required under the Official Information Act 1982, the Ministry will
endeavour to respond to your request no later than 13 August 2021, being
20 working days after the day your request was received.
If we are unable to respond to your request within this time frame, we
will notify you of an extension of that time frame.
If you have any queries related to this request, please do not hesitate to
get in touch.
Ngâ mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
From: OIA Requests
Kia ora Athina,
Thank you for your request for official information, received on 18 July
2021 for:
“1) The due diligence process used to assess the performance and delivery
of Pfizer’s vaccine
2) What information you used to inform your decision that Pfizer has not
been reckless in the development of its vaccine?
3) You quote that "This assessment has been reinforced through Medsafe’s
extensive review of the safety and effectiveness of the vaccine, with
Medsafe granting provisional approval for its use on 3 February 2021".
However, not all of the conditions of Medsafe's provisional approval have
been addressed so how can you truly say their has been an extensive review
of the safety and effectiveness of the vaccine?
4) You quote that " It is not unexpected for pharmaceutical companies to
seek indemnities from governments in circumstances where clinical trials
are restricted, or where a purchase agreement is concluded before full
trials are completed". Which of these categories does the indemnity
granted for the Pfizer vaccination fall under?
5) Please provide the criteria ACC uses to diagnose a "treatment injury"
and what evidence one would have to supply to be provided treatment and
support for injuries caused by a vaccination.
6) Finally, please provide me with details of how many people have
successfully been awarded treatment and support for any vaccine related
injury.”
We are contacting you to clarify parts of your request.
Regarding part 1 please clarify if you are asking about how the
effectiveness of the vaccine is measured? Or are you enquring about
Pfizer’s ability to physically deliver vaccines to New Zealand?
Please also explain part 2 on what type of information you are seeking
regarding the decision that Pfizer has not been reckless in the
development of its vaccine.
We look forward to receiving your response.
Ngâ mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [email address]
show quoted sections
From: OIA Requests
image001.jpg
3K
Download
image002.jpg
2K
Download
H202108633 ACC partial transfer.pdf
264K
Download
View as HTML
Kia ora Athina,
Please find attached a letter relating to your official information act
request.
Ngā mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
Partial transfer of your request for official information (Ref)
show quoted sections
References
Visible links
1. mailto:[email address]
From: OIA Requests
Kia ora Athina,
We are following up on the email below. Are you able to please clarify
parts 1 and 2 of your request?
Can you please respond by 2 August 2021 so that we can consider
your clarification in our response to your request.
Ngâ mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
From: Sharon Chan <[email address]> On Behalf Of OIA Requests
Sent: Friday, 23 July 2021 4:25 pm
To: [FOI #14982 email]
Cc: OIA Requests <[email address]>
Subject: Clarification regarding your request (ref.H202108633)
Kia ora Athina,
Thank you for your request for official information, received on 18 July
2021 for:
“1) The due diligence process used to assess the performance and delivery
of Pfizer’s vaccine
2) What information you used to inform your decision that Pfizer has not
been reckless in the development of its vaccine?
3) You quote that "This assessment has been reinforced through Medsafe’s
extensive review of the safety and effectiveness of the vaccine, with
Medsafe granting provisional approval for its use on 3 February 2021".
However, not all of the conditions of Medsafe's provisional approval have
been addressed so how can you truly say their has been an extensive review
of the safety and effectiveness of the vaccine?
4) You quote that " It is not unexpected for pharmaceutical companies to
seek indemnities from governments in circumstances where clinical trials
are restricted, or where a purchase agreement is concluded before full
trials are completed". Which of these categories does the indemnity
granted for the Pfizer vaccination fall under?
5) Please provide the criteria ACC uses to diagnose a "treatment injury"
and what evidence one would have to supply to be provided treatment and
support for injuries caused by a vaccination.
6) Finally, please provide me with details of how many people have
successfully been awarded treatment and support for any vaccine related
injury.”
We are contacting you to clarify parts of your request.
Regarding part 1 please clarify if you are asking about how the
effectiveness of the vaccine is measured? Or are you enquring about
Pfizer’s ability to physically deliver vaccines to New Zealand?
Please also explain part 2 on what type of information you are seeking
regarding the decision that Pfizer has not been reckless in the
development of its vaccine.
We look forward to receiving your response.
Ngâ mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [2][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
2. mailto:[email address]
From: Athina Andonatou
Dear OIA Requests,
In regards to part 1, I want to know how the effectiveness of the vaccine is measured and what definition of effective is being used? Please do not reply with - ".......doses have been given world wide", I want to know what criteria was and is used to measure effectiveness.
And question 2)
Given Pfizer's history with lawsuits against them for matters such as misbranding with the intent to defraud or mislead; their involvement in defective heart valves that lead to the deaths of more than 100 people; their lawsuit over Rezulin, a diabetes medication that caused patients to die from acute liver failure; criminal charges that it had bribed doctors to prescribe its epilepsy drug Neurontin for indications for which it was not approved and many more https://www.dmlawfirm.com/crimes-of-covi... my question is, please provide the evidence that you used to determine that Pfizer's covid vaccine was fit for purpose. I do not want links, I can find them myself
Athina
Please also explain part 2 on what type of information you are seeking
regarding the decision that Pfizer has not been reckless in the
development of its vaccine.
Yours sincerely,
Athina Andonatou
Virginia Crawford left an annotation ()
The progress of this request is roughly similar to the progress of most of my requests. These government departments are reluctant to divulge ANY information that has not been explicitly disclosed publicly. The FOI system is a JOKE and even reference to the Ombudsman rarely produces a satisfactory result.
Virginia Crawford left an annotation ()
More obfuscation from government departments. Making an FOI request is becoming an exercise in futility.
From: OIA Requests
Kia ora Athina,
Please find attached the response for your request for official
information.
Ngā mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [1][email address]
show quoted sections
References
Visible links
1. mailto:[email address]
From: Government Services
Kia ora Athina
Please find attached our response to your official information request
dated 28 July 2021. If you have any questions about the response you can
contact us at this [1]address, for all other matters please use our
contact form at: [2]https://www.acc.co.nz/contact/ alternatively give us a
call on 0800 101 996.
If you are having trouble viewing the PDF, please ensure you have the
latest version of Adobe Acrobat Reader. To download this freeware please
click [3]here.
Ngâ mihi
Sasha Wood, Manager OIA Services, ACC
ACC cares about the environment – please don’t print this
email
unless it is really necessary. Thank you.
Disclaimer:
"This message and any attachments may contain confidential and privileged
information. If you believe you have received this email in error, please
advise us immediately by return email or telephone and then delete this
email together with all attachments. If you are not the intended
recipient, you are not authorised to use or copy this message or any
attachments or disclose the contents to any other person."
References
Visible links
1. mailto:[email address]
2. https://www.acc.co.nz/contact/
3. https://get.adobe.com/nz/reader/
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence
Offensive? Unsuitable?
Requests for personal information and vexatious requests are not considered valid requests for Official Information (read more).
If you believe this request is not suitable, you can report it for attention by the site administrators
Report this request
victor left an annotation ()
What evidence has our government used to support the validity of the Pcr test?
Responses provided are not evidence they are unsupported opinions and commentary. Example.
- The overall success of the elimination strategy to date.
Is a nonsense comment made in request for evidence of PCR validity.
Each of the 5 dot points are undermined by the MOH OIA responses stating that cycle threshold used as standard in NZ is CT40
And the increasing legal rulings globally against the validity of PCR for the purpose within the covid diagnostic context.
Link to this